0000950170-23-001635.txt : 20230202 0000950170-23-001635.hdr.sgml : 20230202 20230202064025 ACCESSION NUMBER: 0000950170-23-001635 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230131 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230202 DATE AS OF CHANGE: 20230202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270605902 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 23578731 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 8-K 1 krtx-20230131.htm 8-K 8-K
0001771917false00017719172023-01-312023-01-31

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 31, 2023

 

 

Karuna Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38958

27-0605902

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

99 High Street, Floor 26

 

Boston, Massachusetts

 

02110

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 857 449-2244

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.0001

 

KRTX

 

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 1.01 Entry into a Material Definitive Agreement.

On January 31, 2023, Karuna Therapeutics, Inc. (the “Company”) entered into a license agreement (the “Agreement”) with GFB (ABC), LLC (“GFB”), assignee of the assignment estate of Goldfinch Bio, Inc., pursuant to which GFB granted to the Company an exclusive (even as to GFB and its affiliates), worldwide, and sublicensable right and license to certain patent rights and related know-how (the “Licensed Intellectual Property”) to develop, manufacture, and commercialize GFB’s investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates, including the lead clinical-stage candidate known as GFB-887 (collectively, the “Licensed Compounds”). The Company agreed to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one product that contains or comprises a Licensed Compound (a “Licensed Product”) in at least two indications in the United States.

 

Under the terms of the Agreement, the Company is obligated to pay to GFB a $15.0 million upfront payment, and a total of up to $520.0 million for each Licensed Compound upon the achievement of certain development, regulatory and commercial milestones with respect to such Licensed Compound, of which $410.0 million are related to regulatory approval and commercial sales milestones. The Company is also obligated to pay GFB a flat low-single-digit royalty on aggregate net sales of each Licensed Product on a country-by-country basis until the later of: (i) the expiration date of the last valid claim covering the Licensed Product in such country; (ii) the expiration date of regulatory exclusivity with respect to such Licensed Product in such country; and (iii) the date that is a specific period after the first commercial sale of such Licensed Product in such country (collectively, the “Royalty Term”). The royalty rate is subject to reduction on a Licensed Product-by-Licensed Product and country-by-country basis under certain circumstances. In the event that the Company sublicenses to a third party any of the rights to the Licensed Intellectual Property granted under the Agreement, the Company will be obligated to pay GFB royalties within the range of 25% to 35% on any consideration the Company receives from the sublicensee, excluding royalties and certain other payments.

 

Unless earlier terminated, the Agreement will expire on the expiration of the last to expire Royalty Term. Unless the Agreement is earlier terminated, on expiration of each applicable Royalty Term, the Company will have a fully paid-up, irrevocable and perpetual license under the Licensed Intellectual Property to develop, manufacture and commercialize each applicable Licensed Product in the applicable country. Either party may terminate the Agreement for the other party’s material breach, following a customary notice and cure period, or insolvency, other than an insolvency proceeding related to the administration of the assignment estate of Goldfinch Bio, Inc. The Company may terminate the Agreement for any reason upon 90 days written notice to GFB.

 

The foregoing description of the terms of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which the Company intends to file with the Securities and Exchange Commission, with confidential terms redacted, as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Item 7.01 Regulation FD Disclosure.

On February 2, 2023, the Company and GFB issued a joint press release regarding the Agreement. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

99.1

 

Joint press release issued by Karuna Therapeutics, Inc. and GFB (ABC), LLC, dated February 2, 2023

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

KARUNA THERAPEUTICS, INC.

 

 

 

 

Date:

February 2, 2023

By:

/s/ Troy Ignelzi

 

 

 

Troy Ignelzi
Chief Financial Officer

 

 EX-99.1 2 krtx-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates

Karuna to obtain exclusive global license to develop, manufacture, and commercialize multiple TRPC4/5 candidates, including lead clinical-stage candidate GFB-887

Goldfinch Bio assignment estate to receive $15 million upfront payment and up to $520 million in potential milestone payments plus royalties for each TRPC4/5 candidate

Karuna to share details on the planned development of GFB-887 for the treatment of mood and anxiety disorders in the second half of 2023

BOSTON, Mass.– February 2, 2023 -- Karuna Therapeutics, Inc. (NASDAQ: KRTX) and GFB (ABC), LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement under which Karuna will obtain global development, manufacturing, and commercialization rights to Goldfinch Bio’s investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates, including lead clinical-stage candidate GFB-887. Karuna intends to evaluate these candidates as potential treatments for various psychiatric and neurological conditions, starting with GFB-887 for the treatment of mood and anxiety disorders. Karuna expects to share details on the planned development of GFB-887 in the second half of 2023.

“We are focused on addressing the substantial need for new and better treatments in psychiatry through identifying and developing mechanistically novel and distinct medicines,” said Bill Meury, president and chief executive officer of Karuna. “We believe that the TRPC4/5 mechanism could represent a completely novel approach to treating mood and anxiety disorders and complements our existing pipeline of differentiated potential medicines. This agreement aligns with our strategic goal to become a fully integrated neuroscience company with treatments that could offer much more than just incremental benefits to patients, and we look forward to sharing next steps for the program later this year.”

“We are incredibly excited to expand and diversify our development efforts and are encouraged about the potential of TRPC4/5 inhibitors to treat both mood and anxiety disorders based on pre-clinical and clinical data demonstrating anxiolytic and antidepressant properties of these inhibitors,” said Steve Paul, M.D., president of research & development and chief scientific officer. “Our lead candidate in the TRPC4/5 program, GFB-887, has already demonstrated a compelling safety profile in non-clinical and clinical studies. We are fortunate to have found as advanced a clinical stage drug candidate directed

against these important CNS targets and we will now study GFB-887 in various mood and anxiety disorders where there remains a significant unmet medical need for mechanistically novel medicines.”

Under the terms of the agreement, the assignment estate of Goldfinch Bio will receive a $15 million upfront payment and is eligible to receive up to $520 million in milestone payments for each licensed TRPC4/5 candidate, of which $410 million are related to regulatory approval and commercial sales milestones, as well as a flat low-single-digit royalty on any potential global net sales of each licensed product.

“GFB-887 demonstrated compelling benefits in preclinical models of mood and anxiety disorders, and we are delighted that Karuna will leverage its well-established expertise in developing medicines for psychiatric disorders to advance our TRPC4/5 candidates,” commented Anthony Johnson, M.D., president and chief executive officer of Goldfinch Bio. “I am tremendously grateful to all the patients and investigators, and Goldfinch Bio employees, advisors and investors who contributed to progressing GFB-887 and our other TRPC4/5 candidates to this point. It’s my sincere hope that these important contributions will lead to innovative new medicines for patients in need.”

Goldman Sachs & Co. LLC and Cowen served as financial advisors, and Ropes & Gray provided legal counsel to Goldfinch Bio.

About Karuna

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.

Karuna Therapeutics Forward Looking Statements

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the potential of the TRPC4/5 program, including GFB-887, to treat mood and anxiety disorders, our goals to develop and commercialize our product candidates and

other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our ability to generate positive clinical trial results for our product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, and other risks set forth under the heading “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021. Our actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Karuna Therapeutics Contacts:

Investors:
Alexis Smith
518-338-8990
asmith@karunatx.com

Media:
Bob Josefsberg
bjosefsberg@karunatx.com
646-734-3584

Goldfinch Bio Contact:
Kyle Kuvalanka
kkuvalanka@goldfinchbio.com

 EX-101.SCH 3 krtx-20230131.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 4 krtx-20230131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 5 krtx-20230131_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Jan. 31, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 31, 2023
Entity Registrant Name Karuna Therapeutics, Inc.
Entity Central Index Key 0001771917
Entity Emerging Growth Company false
Securities Act File Number 001-38958
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 27-0605902
Entity Address, Address Line One 99 High Street, Floor 26
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 857
Local Phone Number 449-2244
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001
Trading Symbol KRTX
Security Exchange Name NASDAQ
XML 7 krtx-20230131_htm.xml IDEA: XBRL DOCUMENT 0001771917 2023-01-31 2023-01-31 0001771917 false 8-K 2023-01-31 Karuna Therapeutics, Inc. DE 001-38958 27-0605902 99 High Street, Floor 26 Boston MA 02110 857 449-2244 false false false false Common stock, par value $0.0001 KRTX NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports krtx-20230131.htm krtx-20230131.xsd krtx-20230131_lab.xml krtx-20230131_pre.xml krtx-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "krtx-20230131.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "krtx-20230131.htm" ] }, "labelLink": { "local": [ "krtx-20230131_lab.xml" ] }, "presentationLink": { "local": [ "krtx-20230131_pre.xml" ] }, "schema": { "local": [ "krtx-20230131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "krtx", "nsuri": "http://karunatx.com/20230131", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "krtx-20230131.htm", "contextRef": "C_102bc0f8-edff-4651-9600-7f995a05724d", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "krtx-20230131.htm", "contextRef": "C_102bc0f8-edff-4651-9600-7f995a05724d", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://karunatx.com/20230131/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-001635-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-001635-xbrl.zip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end